Portfolio

Transforming UK university research into global impact

Meet our companies

The companies we invest in are developing groundbreaking university research into successful businesses, spanning sectors including Life Sciences, AI, Quantum Computing, Advanced Materials, Genomics, CleanTech, Future of Mobility, MedTech and Big Data.

Explore our portfolio

Antibody technology for pet health
PetMedix is utilising tried and tested antibody technology to develop treatments for diseases in companion animals. Monoclonal antibodies are now a hugely important human drug class but are in their infancy in the treatment of animals. PetMedix will take tried and tested techniques and apply them to the treatment of dogs and cats.
Status
Seeded in 2021
Institution
Cambridge
  • Life Sciences

PetMedix

PetMedix is utilising tried and tested antibody technology to develop treatments for diseases in companion animals. Monoclonal antibodies are now a hugely important human drug class but are in their infancy in the treatment of animals. PetMedix will take tried and tested techniques and apply them to the treatment of dogs and cats.
Sector
Life Sciences
Institution
Cambridge

Your Portfolio

If you are an existing investor and want to find out more about your portfolio, visit the investor portal.
Visit Investor Portal

Latest from Parkwalk and our portfolio

7 May 2026

Quantum Motion raises $160m Series C funding round

Quantum Computing
Portfolio
17 April 2026

HealthTech portfolio companies feature in Tech Funding News

Portfolio
8 April 2026

K3 Metrology raises £2.75m Seed funding round

Hardware
Portfolio
View all Parkwalk and portfolio news

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.